Emerging Drug Developer: Juvaris BioTherapeutics
Kleiner Perkins was so impressed by the research work underway at Juvaris BioTherapeutics, the venture group ended up investing $12 million last year in the company's Series A round. And last March, Kleiner Perkins helped engineer the arrival of Grant Pickering to run the vaccine company with an eye to taking Juvaris to proof-of-concept data on a slate of vaccine development programs.
Just weeks ago Juvaris launched its first clinical study, a Phase I trial of a vaccine adjuvant--JVRS-100--combined with a commercially available vaccine for seasonal influenza. And now the small biotech has a full slate of programs nearing the clinic. By the end of this year, the developer plans to have its first look at efficacy data in humans and a new round of venture capital in the bank. Article
Be the first to comment
More stories about Juvaris BioTherapeutics
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
